We are currently in a difficult market but we will soon have a battery arms race. Strategic assets will continue to be prized by acquirers.https://www.linkedin.com/feed/update/urn:li:activity:6550468073533562880
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%